{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:06:55Z","timestamp":1776085615298,"version":"3.50.1"},"reference-count":25,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T00:00:00Z","timestamp":1775952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Backgroundand Objectives: Targeted therapies are increasingly used in the management of chronic lymphocytic leukemia (CLL); however, real-world data from routine clinical practice remain limited. Materials and Methods: We performed a retrospective analysis of 47 patients with CLL who received at least one targeted therapy at a tertiary university hospital. Clinical characteristics, treatment responses, and adverse events were assessed. A total of 58 treatment events were included. Results: Obinutuzumab, ibrutinib, and venetoclax were administered in 34.5%, 46.5%, and 19.0% of treatment events, respectively. Numerically higher response rates were observed in treatment events involving obinutuzumab compared with ibrutinib and venetoclax (92.9% vs. 54.5% and 55.6%, respectively); however, treatment allocation was not randomized and these findings should be interpreted descriptively. Median overall survival from initiation of the first targeted therapy was 30.9 months. Adverse events occurred in more than 80% of treatment events. Neutropenia was more frequent with obinutuzumab and venetoclax, whereas bleeding events were more common with ibrutinib. Conclusions: In this real-world cohort, targeted therapies showed response patterns and safety findings consistent with routine clinical practice. Obinutuzumab was more frequently prescribed in older and more comorbid patients, reflecting treatment patterns rather than comparative superiority. These findings should be considered descriptive and hypothesis-generating, given the retrospective and single-center design.<\/jats:p>","DOI":"10.3390\/medicina62040736","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T11:38:26Z","timestamp":1776080306000},"page":"736","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Treatment Patterns and Safety Outcomes of Targeted Therapies in a Single-Center Chronic Lymphocytic Leukemia Cohort"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6594-1712","authenticated-orcid":false,"given":"Seda","family":"Jeral Evin\u00e7","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Cerrahpa\u015fa Faculty of Medicine, Istanbul University-Cerrahpa\u015fa, 34098 \u0130stanbul, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c7a\u011fla","family":"Ey\u00fcpler Akmercan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Istanbul G\u00f6ztepe Prof. Dr. S\u00fcleyman Yal\u00e7\u0131n City Hospital, Istanbul Medeniyet University, 34722 \u0130stanbul, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tar\u0131k","family":"Ercan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical Park G\u00f6ztepe Hospital, Bah\u00e7e\u015fehir University, 34732 \u0130stanbul, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma","family":"Ar\u0131kan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, Marmara University, 34854 \u0130stanbul, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meral Ulukoylu","family":"Meng\u00fc\u00e7","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, Marmara University, 34854 \u0130stanbul, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2690-8581","authenticated-orcid":false,"given":"Tayfur","family":"Topta\u015f","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, Marmara University, 34854 \u0130stanbul, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I\u015f\u0131k","family":"Atag\u00fcnd\u00fcz","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, Marmara University, 34854 \u0130stanbul, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T\u00fclin","family":"Tu\u011flular","sequence":"additional","affiliation":[{"name":"Department of Hematology, Academic Hospital, 34718 \u0130stanbul, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asu Ferg\u00fcn","family":"Y\u0131lmaz","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, Marmara University, 34854 \u0130stanbul, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2023.1946","article-title":"Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review","volume":"329","author":"Shadman","year":"2023","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: Updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood.2024025525","article-title":"The MURANO study: Final analysis and retreatment\/crossover substudy results of VenR for patients with relapsed\/refractory CLL","volume":"145","author":"Kater","year":"2025","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood.2024028205","article-title":"Final analysis of the RESONATE-2 study: Up to 10 years of follow-up of first-line ibrutinib treatment for CLL\/SLL","volume":"146","author":"Burger","year":"2025","journal-title":"Blood"},{"key":"ref_11","unstructured":"National Cancer Institute (2026, April 01). Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03, Available online: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf."},{"key":"ref_12","unstructured":"National Cancer Institute (2026, April 01). Cancer Stat Facts: Leukemia\u2014Chronic Lymphocytic Leukemia (CLL), Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html."},{"key":"ref_13","first-page":"421","article-title":"Efficacy and safety of the obinutuzumab-chlorambucil combination in the frontline treatment of elderly CLL patients with comorbidities\u2014Polish Adult Leukemia Group (PALG) real-life analysis","volume":"128","author":"Jurczak","year":"2018","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25766","article-title":"Frontline treatment with the combination obinutuzumab \u00b1 chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group","volume":"95","author":"Herishanu","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/bjh.17326","article-title":"Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed\/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study","volume":"193","author":"Stilgenbauer","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/bcp.14440","article-title":"Patterns of use and safety of ibrutinib in real-life practice","volume":"87","author":"Allouchery","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3324\/haematol.2018.193615","article-title":"Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1080\/10428194.2017.1410890","article-title":"Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia","volume":"59","author":"Gay","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: A multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood.2018882555","article-title":"Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables","volume":"134","author":"Roberts","year":"2019","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Broccoli, A., Argnani, L., Morigi, A., Nanni, L., Casadei, B., Pellegrini, C., Stefoni, V., and Zinzani, P.L. (2021). Long-Term Efficacy and Safety of Ibrutinib in the Treatment of CLL Patients: A Real Life Experience. J. Clin. Med., 10.","DOI":"10.3390\/jcm10245845"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions","volume":"124","author":"Levade","year":"2014","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/4\/736\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T12:30:59Z","timestamp":1776083459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/4\/736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,12]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["medicina62040736"],"URL":"https:\/\/doi.org\/10.3390\/medicina62040736","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,12]]}}}